601 A
Alternative Names: 601; 601-A; 601A-AMD; 601A-DME; 601A-pmCNV; 601A-RVO; Anti-VEGF monoclonal antibody - Sunshine Guojian PharmaceuticalLatest Information Update: 28 Aug 2024
At a glance
- Originator 3SBio
- Developer 3SBio; Sunshine Guojian Pharmaceutical
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diabetic macular oedema
- Phase II Choroidal neovascularisation
- No development reported Age-related macular degeneration; Wet age-related macular degeneration
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in China (Parenteral, Injection)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Wet age-related macular degeneration(Treatment-experienced) in China (Intravitreous, Injection)
- 27 Dec 2022 Phase-III clinical trials in Diabetic macular oedema in China (Intravitreous) (NCT05520177)